Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils

Pulmonary Pharmacology and Therapeutics

Volumn 43, Issue , 2017, Pages 39-45

  Brusselle, Guy ^a   Germinaro, Matthew ^b   Weiss, Sivan ^b   Zangrilli, James ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b TEVA PHARMACEUTICALS   (Israel)

Author keywords

Asthma; Late onset; Reslizumab

Indexed keywords

CREATININE; PHOSPHOTRANSFERASE; RESLIZUMAB; ANTIASTHMATIC AGENT; INTERLEUKIN 5; MONOCLONAL ANTIBODY;

ABNORMAL LABORATORY RESULT; ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BACKACHE; BRONCHITIS; CHILD; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EMERGENCY WARD; ENZYME BLOOD LEVEL; EOSINOPHIL COUNT; EOSINOPHILIC ASTHMA; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HEADACHE; HEART DISEASE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFECTION COMPLICATION; INFESTATION; INFLUENZA; INJECTION SITE REACTION; INJURY; INTOXICATION; LATE ONSET DISORDER; LENGTH OF STAY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; ONSET AGE; PATIENT SAFETY; PATIENT-REPORTED OUTCOME; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; RHINITIS; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SINUSITIS; SKIN DISEASE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULAR DISEASE; ANTAGONISTS AND INHIBITORS; EOSINOPHIL; LUNG FUNCTION TEST; META ANALYSIS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTERLEUKIN-5; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85013301629     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2017.01.011     Document Type: Article

References (17)

1. [1] Wenzel, S.E., Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 18:5 (2012), 716–725.
2. [2] Brusselle, G.G., Maes, T., Bracke, K.R., Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat. Med. 19:8 (2013), 977–979.
3. [3] Chung, K.F., Defining phenotypes in asthma: a step towards personalized medicine. Drugs 74:7 (2014), 719–728.
4. [4] Castro, M., Zangrilli, J., Wechsler, M.E., Bateman, E.D., Brusselle, G.G., Bardin, P., et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3:5 (2015), 355–366.
5. [5] Egan, R.W., Athwal, D., Bodmer, M.W., Carter, J.M., Chapman, R.W., Chou, C.C., et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung 49:9 (1999), 779–790.
6. [6] Kips, J.C., O'Connor, B.J., Langley, S.J., Woodcock, A., Kerstjens, H.A., Postma, D.S., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med. 167:12 (2003), 1655–1659.
7. [7] Castro, M., Mathur, S., Hargreave, F., Boulet, L.P., Xie, F., Young, J., et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 184:10 (2011), 1125–1132.
8. [8] Moore, W.C., Meyers, D.A., Wenzel, S.E., Teague, W.G., Li, H., Li, X., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am. J. Respir. Crit. Care Med. 181:4 (2010), 315–323.
9. [9] Sood, A., Qualls, C., Schuyler, M., Arynchyn, A., Alvarado, J.H., Smith, L.J., et al. Adult-onset asthma becomes the dominant phenotype among women by age 40 years. The longitudinal CARDIA study. Ann. Am. Thorac. Soc. 10:3 (2013), 188–197.
10. [10] Amelink, M., de Groot, J.C., de Nijs, S.B., Lutter, R., Zwinderman, A.H., Sterk, P.J., et al. Severe adult-onset asthma: a distinct phenotype. J. Allergy Clin. Immunol. 132:2 (2013), 336–341.
11. [11] Martinez, F.D., Wright, A.L., Taussig, L.M., Holberg, C.J., Halonen, M., Morgan, W.J., Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N. Engl. J. Med. 332:3 (1995), 133–138.
12. [12] de Nijs, S.B., Venekamp, L.N., Bel, E.H., Adult-onset asthma: is it really different?. Eur. Respir. Rev. 22:127 (2013), 44–52.
13. [13] de Groot, J.C., ten Brinke, A., Bel, E.H.D., Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res., 1(1), 2015.
14. [14] Weinstein SF, Germinaro M, Bardin P, Korn S, Bateman ED. Efficacy of reslizumab with asthma, chronic sinusitis with nasal polyps and elevated blood eosinophils. J. Allergy Clin. Immunol. 137(2):AB86.
15. [15] Fahy, J.V., Type 2 inflammation in asthma–present in most, absent in many. Nat. Rev. Immunol. 15:1 (2015), 57–65.
16. [16] Christianson, C.A., Goplen, N.P., Zafar, I., Irvin, C., Good, J.T. Jr., Rollins, D.R., et al. Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33. J. Allergy Clin. Immunol., 136(1), 2015 59–68.e14.
17. [17] Smith, S.G., Gugilla, A., Mukherjee, M., Merim, K., Irshad, A., Tang, W., et al. Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma. J. Allergy Clin. Immunol. 135:6 (2015), 1594–1602.